Maverick's Update

Nothin’ like the end of a global pandemic to make you want to party. Summer events, festivals, and parties (California, Chicago, NYC) are happening all over. People are not only going to these events but are proving that they don’t remember how to enjoy things the regular way. Case in point: fans of Taylor Swift are not only paying ridiculous amounts for a ticket to see an Eras Tour concert, they are also wearing adult diapers so they don’t have to miss a song for an inconvenient bio break. We encourage everyone to use the facilities before we describe other parties and moments of Nature in the One Thoughtful Paragraph.

If you are feeling left out of the party scene, our health information policy news may help:

• No plans for July 4^th? No problem. The White House Office of Science and Technology Policy (OSTP) is inviting you to submit answers to 29 questions about how the U.S. should prioritize and regulate artificial intelligence. Each inquiry in its Request for Information requires a PhD-dissertation-level response by July 7, 2023. If you hate fireworks, maybe tackle Question #17 (hint: it is more than one question): What will the principal benefits of AI be for the people of the United States? How can the United States best capture the benefits of AI across the economy, in domains such as education, health, and transportation? How can AI be harnessed to improve consumer access to and reduce costs associated with products and services? How can AI be used to increase competition and lower barriers to entry across the economy?
• The American Medical Association (AMA) is inviting technology developers to its medical code party. Its new partnership with HL7 combines Fast Healthcare Interoperability Resources (FHIR) with the AMA’s Current Procedure Terminology (CPT) code set to advance interoperability in clinical care, research, and public health. SO much fun.
• The FDA is invited to speak at the Center for U.S. Policy’s next party. The agency is reviewing the Center’s citizen petition, which asks it to issue a warning notice that Bamboo Health’s NarxCare software – a clinical decision support (CDS) tool that evaluates a patient’s criminal history, electronic health records, and medical claims data to make more informed painkiller prescribing decisions – is a misbranded medical device.

One Thoughtful Paragraph